TSI Health Sciences

TSI Health Sciences, Missoula, MT, has announced that its Pureflex chondroitin sulfate sodium USP grade ingredients have been found to be in compliance with the requirements of the USP (United States Pharmacopeia) Ingredient Verification Program. The ingredients were approved based upon a GMP audit of the company’s wholly owned TSI-Jiangyin Pharmaceutical Co., Ltd. dedicated chondroitin sulfate manufacturing facility. Additionally, USP conducted a review of TSI’s manufacturing and quality control documentation, along with a laboratory evaluation of ingredient samples for compliance with label claims and USP program requirements. The USP verification means the ingredients are consistent in quality from batch to batch; meet label or certificate of analysis claims for identity, strength, purity and quality; are prepared in accordance with accepted manufacturing processes; and meet requirements for acceptable limits of contamination.